Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Global progress towards hepatitis C elimination still blocked by cost of treatment, lack of diagnosis

Nine countries – Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar – are on course to eliminate hepatitis C by 2030, according to

Published
01 November 2017
By
Keith Alcorn
Nine countries now on track to eliminate hepatitis

New data on hepatitis C released by the Polaris Observatory and presented today at the World Hepatitis Summit (WHS) in Sao Paulo, Brazil show that nine countries — Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar — are on course to eliminate hepatitis C by 2030.

Published
01 November 2017
From
World Hepatitis Summit
MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, sofosbuvir and daclatasvir, for as low as US$1.40 per day, or US$120 per 12-week treatment course.

Published
31 October 2017
From
Intellectual Property Watch
Close to 3 million people access hepatitis C cure

On the eve of the World Hepatitis Summit in Brazil, WHO reports increasing global momentum in the response to viral hepatitis. A record 3 million people were able to obtain treatment for hepatitis C over the past two years, and 2.8 million more people embarked on lifelong treatment for hepatitis B in 2016.

Published
31 October 2017
From
World Health Organization
Gilead HCV drug sales down in 2017 third quarter compared with 2016

Gilead announced that combined third-quarter sales for Harvoni, Sovaldi, Epclusa and Vosevi were $2.2 billion compared with $3.3 billion the third quarter of 2016, related to fewer patients initiating treatment and increased drug competition.

Published
31 October 2017
From
Healio
More than 6 million treated for hepatitis globally

Since 2015, nearly 3 million people initiated treatment for hepatitis C, and in 2016 alone nearly 3 million initiated hepatitis B treatment, according to an announcement from the World Health Organization in conjunction with the World Hepatitis Summit.

Published
31 October 2017
From
Healio
Hepatitis C test-and-treat programme reduces HCV by two-thirds among men who have sex with men in Swiss HIV Cohort

A systematic policy of test-and-treat cured 99% of men who have sex with men with hepatitis C in the Swiss HIV Cohort in an 8-month period and

Published
30 October 2017
By
Keith Alcorn
Curing hepatitis C with DAAs linked to 71% reduction in liver cancer

People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting

Published
30 October 2017
By
Liz Highleyman
Hepatitis C halved in Spanish people living with HIV in one year due to treatment

Spain is making dramatic progress towards eliminating hepatitis C in people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón, Madrid,

Published
27 October 2017
By
Keith Alcorn
New EACS treatment guidelines

Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as

Published
26 October 2017
By
Keith Alcorn
← First12345...95Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.